Pardes Biosciences Enters Into Agreement To Be Acquired By MediPacific, Inc. For Between $2.02 And $2.19 In Cash Per Share Plus Contingent Value Rights
Portfolio Pulse from Benzinga Newsdesk
Pardes Biosciences has agreed to be acquired by MediPacific, Inc. for between $2.02 and $2.19 in cash per share, plus contingent value rights. The deal is subject to shareholder approval.
July 17, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pardes Biosciences is to be acquired by MediPacific, Inc. This could potentially increase the value of PRDS shares in the short term.
The acquisition of Pardes Biosciences by MediPacific, Inc. could potentially increase the value of PRDS shares in the short term. The acquisition price of between $2.02 and $2.19 per share is likely to set a floor for the stock price, providing a level of downside protection for shareholders. Additionally, the inclusion of contingent value rights in the deal provides potential for further upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100